Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF1K16 Phase 1 SAD Study in Healthy Subjects
NCT05386823Phase 1Completed
- Sponsor
- HighField Biopharmaceuticals
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HF1K16 in solid tumor (3 arms), sponsored by HighField Biopharmaceuticals. Primary endpoints: Number of Participants With Adverse Event (AE) and Severe Adverse Event (SAE) and Number of Participants With Dose-Limiting Toxicities (DLTs). Started Mar 2021; status: completed.
02
Drugs
HF1K16
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05386823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386823.